Cohance Lifesciences Ltd: Stock Analysis & Fundamentals

Updated this week

Cohance Lifesciences Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 38.5. ROE: 12.7%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

📊Debt increased 62% YoY — leverage rising

👔Promoter buying — stake up 7.4% this quarter

🌐FII stake decreased 4.2% this quarter

🏛️DII accumulation — stake up 3.9%

Key Numbers

Current Price

₹303

Market Cap

11.6K Cr

Valuation

N/A

Other Top Pharma - API & CRAMS Stocks Beating Nifty 500

Gland Pharma Ltd

Average

+15.9%

Acutaas Chemicals Ltd

SMS Pharmaceuticals Ltd

Average • 12w streak

+37.7%

← Back to Pharma - API & CRAMS Dashboard

Frequently Asked Questions: Cohance Lifesciences Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Cohance Lifesciences Ltd's latest quarterly results?

Cohance Lifesciences Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -81.0%
Revenue Growth YoY: -19.4%
Operating Margin: 18.0%

What is Cohance Lifesciences Ltd's current PE ratio?

Cohance Lifesciences Ltd's current PE ratio is 38.5x.

Current PE: 38.5x
Market Cap: 11.6K Cr

What is Cohance Lifesciences Ltd's price-to-book ratio?

Cohance Lifesciences Ltd's price-to-book ratio is 3.1x.

Price-to-Book (P/B): 3.1x
Book Value per Share: ₹99
Current Price: ₹303

Is Cohance Lifesciences Ltd a fundamentally strong company?

Cohance Lifesciences Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 15.0%

Is Cohance Lifesciences Ltd debt free?

Cohance Lifesciences Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹451 Cr

What is Cohance Lifesciences Ltd's return on equity (ROE) and ROCE?

Cohance Lifesciences Ltd's return ratios over recent years

FY2023: ROCE 32.0%
FY2024: ROCE 19.0%
FY2025: ROCE 15.0%

Is Cohance Lifesciences Ltd's cash flow positive?

Cohance Lifesciences Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹288 Cr
Free Cash Flow (FCF): ₹35 Cr
CFO/PAT Ratio: 109% (strong cash conversion)

What is Cohance Lifesciences Ltd's dividend yield?

Cohance Lifesciences Ltd currently does not pay a significant dividend (yield 0.00%).

Dividend Yield: 0.00%
Current Price: ₹303

Who holds Cohance Lifesciences Ltd shares — promoters, FII, DII?

Cohance Lifesciences Ltd's shareholding pattern (Dec 2025)

Promoters: 57.5%
FII (Foreign): 6.0%
DII (Domestic): 21.6%
Public: 14.9%

Is promoter holding increasing or decreasing in Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 57.5% (Dec 2025)
Previous Quarter: 57.5% (Sep 2025)
Change: 0.00% (stable)

Is Cohance Lifesciences Ltd a new momentum entry or an established outperformer?

Cohance Lifesciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Cohance Lifesciences Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Cohance Lifesciences Ltd may be worth studying

Cash flow is positive — CFO ₹288 Cr

What is the investment thesis for Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd investment thesis summary:

What is the future outlook for Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.